Advisory Committee on Immunization Practices (ACIP) Vaccine Updates - 2011
Zoster, Tdap, Meningococcal, and Pneumococcal Vaccine

**Zoster** Zostavax (Merck)
- Approved age range is now age 50 years and older
- Zostavax is indicated to prevent herpes zoster (shingles)
- Currently, many providers are experiencing delays in receiving shipments of this vaccine

**Tdap** [http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#tdap](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#tdap)
Adacel (Sanofi Pasteur) and Boostrix (GSK) Due to the ongoing pertussis epidemic, SFDPH recommendations continue to be more inclusive than national ACIP recommendations, but ACIP recommendations have expanded:
- Ideal time for Tdap administration remains during 11-12 year-old preventive health-care visit
- Give Tdap regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine
- Give Tdap to any adult wanting protection, including those aged 65 years and older, and especially those having close contact with infants aged less than 12 months and pregnant women
- Use Tdap in children aged 7 through 10 years with an incomplete DTaP series
- Vaccinate all healthcare personnel who have not previously received Tdap regardless of interval since last Td dose

**Meningococcal** [http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#mening](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#mening)
Menveo (Novartis) and Menactra (Sanofi Pasteur)
- Routinely vaccinate pre-adolescents at age 11 or 12 years, and give a booster dose at age 16 years
- Administer a 2-dose primary series 2 months apart for persons aged 2 through 54 years with persistent complement component deficiency and functional or anatomic asplenia, and for adolescents with HIV infection

**Pneumococcal** [http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#pcv](http://www.cdc.gov/vaccines/pubs/ACIP-list.htm#pcv)
- **PPSV23** - use of 23-valent pneumococcal polysaccharide vaccine among adults aged ≥19 years:
  - Indications now include smoking (present or within past 10 years) and asthma
  - Routine use is no longer recommended for Alaska Natives or American Indians aged <65 years unless they have medical or other indications
  - Revaccination is not routinely recommended, but a second dose of PPSV23 is recommended 5 years after the first dose for persons aged 19-64 years with indicated chronic conditions
  - All persons should be vaccinated with PPSV23 at age 65 years. Those who received PPSV23 before age 65 years for any indication should receive another dose at age 65 or later if at least 5 years have passed since the previous dose
- **PCV13** - use among infants and young children aged <6 years:
  - Administer routine vaccination of all children aged 2–59 months
  - Use in children aged 60–71 months with underlying medical conditions
  - Use PCV13 in children who received ≥1 dose of PCV7 previously
  - Administer PPSV23 to children aged 2–18 years with underlying medical conditions after completing all recommended doses of PCV13

Visit our website for links to updated vaccine recommendations: [http://sfcdc.org/vaxfax](http://sfcdc.org/vaxfax)